The new 13,000 square metre facility, first announced last October, will be constructed on a site adjacent to MSD’s existing Carlow plant in Ireland South East and will focus on the production of vaccines and biologics. It is scheduled to commence manufacturing operations in 2022 and will employ an additional 170 staff and 100 contractor staff when operational. The build phase will also see approximately 700 tradespeople employed on site.
MSD already employs over 400 people in Carlow and is involved in the manufacture of multiple vaccines and biologics in the MSD product portfolio. The existing site opened in 2008 and was MSD’s first vaccines facility outside of the US.
Speaking at a ceremony to mark the commencement of the construction phase, Sanat Chattopadhyay, President, MSD Global Manufacturing Division, stated that, “Due to increased global demand for MSD’s medicines and vaccines, our company is investing significantly in expanding our manufacturing and supply capabilities. The construction of a second manufacturing facility at the site of our existing operation in Carlow is part of this exciting investment. The decision to further invest in Carlow is a real testament to the talent of the current Carlow team and MSD Ireland’s wider employee base. This new investment reinforces MSD’s commitment to Ireland, further strengthening our 50-year strong legacy here. Ireland has been a gracious and supportive host for MSD for many years, and we anticipate doing business here for many years in the future.”